Clinical trials: Oligometastases
Spinal Metastases, Spinal Tumor
En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
The purpose of this clinical trial is to explore the impact of En bloc surgery and separation surgery combined with radiation therapy on the prognosis and survival of patients with spinal oligometastatic cancer, describe the…
- Conditions
- Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor
- Trial name
- NCT06120426
- Testing
- total en bloc spondylectomy
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Oligometastatic Disease, Prostate Cancer
Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma
The purpose of this study is to evaluate the outcomes of patients treated with an high dose radiation regimen using either stereotactic hypofractionated or normofractionated radiotherapy for oligometastatic prostate cancer and to…
- Trial name
- Oli-P (NCT02264379)
- Testing
- normal fractionated irradiation, hypo fractionated irradiation
- Where
- 2 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Technische Universität Dresden
Oligometastases
SABR-SCAN Trial for Pulmonary Oligometastases
Rationale: SABR (Stereotactic ablative radiotherapy) is one of the standard treatment options besides surgical resection for limited lung metastases (oligometastases) from colorectal cancer.
- Trial name
- SABR-SCAN (NCT02414334)
- Testing
- Stereotactic Ablative Radiotherapy (SABR)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Breast Cancer, Metastatic, Metastatic Breast Cancer
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
The goal of this clinical trial is to assess Stereotactic Ablative Radiotherapy (SABR) as a method to delay a change in systemic therapy in patients with oligoprogressive ER-positive, HER2-negative advanced breast cancer.
- Trial name
- AVATARII (NCT06882499)
- Testing
- Stereotactic Ablative Radiotherapy, Physician's choice of systemic treatment
- Volunteers
- 74 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer Metastatic
Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone
This study is to examine whether radical prostatectomy can impact survival and quality-of-life in men with oligo-metastatic prostate cancer.
- Trial name
- NCT03988686
- Testing
- Radical prostatectomy plus standard care, Standard of care for metastatic prostate cancer
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Oligometastatic Disease, Oligoprogression
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs.
- Conditions
- Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life
- Trial name
- NCT05784428
- Testing
- Single fraction SABR, Multiple fraction SABR, QoL reporting alone
- Where
- 14 sites in Canada, Ireland
- Volunteers
- 598 people
- Sponsor
- Robert Olson
Adaptive Radiotherapy, Stereotactic Body Radiotherapy
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with early-stage non-small cell lung cancer (NSCLC) or…
- Conditions
- Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
- Trial name
- NCT06542159
- Testing
- Online adaptive SBRT, Conventional SBRT
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Oligo-metastatic Cancer
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
The combination of local consolidative therapy for oligometastases with systemic therapy offers the potential for clinical cure and significantly prolongs survival in a subset of patients with advanced metastatic disease.
- Trial name
- NCT07481799
- Testing
- Becotatug Vedotin, SBRT, Systemic Therapy/Standard of Care
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Ming-Yuan Chen
Stage IV Non-small Cell Lung Cancer
Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.
Aggressive therapy may improve survival in synchronous oligometastatic NSCLC and the goal of this clinical trial is to assess the efficacy and safety of local definitive radiotherapy in this subset of patients.
- Trial name
- NCT03119519
- Testing
- Local Definitive Radiotherapy, No Local Definitive Radiotherapy
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Southern Medical University, China
Brain Oligometastases
HF-SRT vs. HS-WBRT in Treating Patients With Brain Oligometastases
[Background] For newly-diagnosed patients with brain metastases (BMs), conventional whole-brain radiotherapy (WBRT) might still remain a common palliative management.
- Trial name
- NCT05807165
- Testing
- Hypofractionated Stereotactic Radiotherapy (HF-SRT), Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine
- Where
- Taiwan
- Volunteers
- 115 people
- Sponsor
- Chang Gung Memorial Hospital
Colorectal Cancer
Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer
Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer
- Trial name
- NCT02909114
- Testing
- Stereotactic body radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jing Jin, M.D.
Colorectal Neoplasms Malignant
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Colorectal cancer (CRC) is the third most common cancer worldwide. Surgical resection is one of the primary treatment options for CRC; however, postoperative recurrence remains a significant clinical challenge for both the…
- Trial name
- NCT06778382
- Testing
- Oligometastasis Treatment
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shandong Cancer Hospital and Institute
Advanced Esophageal Squamous Carcinoma With Oligometastases
Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.
A randomized, prospective phase II trial was conducted to explore the timing of radiotherapy intervention in combination with chemotherapy and immunotherap in order to provide an effective treatment for patients with advanced…
- Trial name
- NCT06143722
- Testing
- simultaneous with radiotherapy, synchronous with radiotherapy
- Volunteers
- 63 people
- Sponsor
- West China Hospital
Lung Cancer
Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location
MAGELLAN is a phase-I dose escalation trial that aims to identify the maximum tolerated dose (MTD) of MR-guided SBRT of ultracentral lung Tumors (primary objective).
- Trial name
- MAGELLAN (NCT04925583)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- University Hospital Heidelberg
Melanoma Metastatic
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
The purpose of this research is to evaluate the addition of radiotherapy to the standard immunotherapy drugs that are given to patients with advanced or metastatic melanoma that has spread to other parts of the body.
- Trial name
- AXIOM (NCT06767306)
- Testing
- Stereotactic Body Radiotherapy (extracranial) concurrent with Immunotherapy, Immunotherapy alone
- Where
- 5 sites in Australia, Canada
- Volunteers
- 129 people
- Sponsor
- Melanoma Institute Australia
Oligometastatic Prostate Cancer
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate…
- Trial name
- PROMPT (NCT04610372)
- Testing
- Hypofractionated external beam radiotherapy, High dose rate brachytherapy, Permanent seed implant
- Where
- 4 sites in Canada
- Volunteers
- 168 people
- Sponsor
- British Columbia Cancer Agency
NSCLC Stage IV, EGFR Activating Mutation
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
This study is an open-label, single-arm phase 2 trial to evaluate the efficacy and safety of stereotactic radiotherapy (SRT) for patients with oligo-residual NSCLC after 3rd generation EGFR-TKIs.
- Trial name
- NCT04764214
- Testing
- 3rd generation EGFR-TKI, Consolidative SRT
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fudan University
Prostatic Cancer, Castration-Resistant
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
In earlier stages of prostate cancer, male sexual hormones (androgens) stimulate the growth of cancer cells. Castration-resistant prostate cancer (CRPC) means that the prostate cancer continued to grow despite patients are taking…
- Trial name
- PEACE8 (NCT06276465)
- Testing
- Darolutamide 300 mg, Stereotactic body radiation therapy, Androgen deprivation therapy
- Where
- 4 sites in France
- Volunteers
- 336 people
- Sponsor
- UNICANCER
Metastatic Tumors
Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases
This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).
- Trial name
- NCT02933242
- Testing
- Stereotactic Ablative Body Radiotherapy
- Where
- Canada
- Volunteers
- 399 people
- Sponsor
- British Columbia Cancer Agency
Brain Metastases, Adult
A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT
Background: For newly-diagnosed patients with brain metastasis, conventional whole-brain radiation therapy (WBRT) might still remain a common palliative management even for those with brain oligometastases.
- Trial name
- HF-SRT (NCT04805255)
- Testing
- Hypofractionated Stereotactic Radiotherapy
- Where
- 2 sites in Taiwan
- Volunteers
- 135 people
- Sponsor
- Chang Gung Memorial Hospital